Dapagliflozin Mitigates Doxorubicin-Caused Myocardium Damage by Regulating AKT-Mediated Oxidative Stress, Cardiac Remodeling, and Inflammation
Doxorubicin (Dox) is a commonly used anthracycline chemotherapy with a side effect of cardiotoxicity, which may increase the risk of heart failure for cancer patients. Although various studies have demonstrated the cardioprotective property of dapagliflozin (DAPA), a sodium-glucose cotransporter 2 i...
Main Authors: | Pei-Ling Hsieh, Pei-Ming Chu, Hui-Ching Cheng, Yu-Ting Huang, Wan-Ching Chou, Kun-Ling Tsai, Shih-Hung Chan |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-09-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/23/17/10146 |
Similar Items
-
Comparison of Cardioprotective Effects of Dapagliflozin and Trimetazidine in the Model of Doxorubicin-Cyclophosphamide Cardiotoxicity
by: A. A. Avagimyan, et al.
Published: (2023-11-01) -
Dapagliflozin May Protect Against Doxorubicin-Induced Cardiotoxicity
by: Sebahat Ulusan, et al.
Published: (2023-05-01) -
RRM2 Alleviates Doxorubicin-Induced Cardiotoxicity through the AKT/mTOR Signaling Pathway
by: Yuheng Jiao, et al.
Published: (2022-02-01) -
Influence of trimetazidine on myocardium energy balance during chemotherapy with doxorubicin and cyclophosphamide
by: A. A. Avagimyan
Published: (2022-06-01) -
Lipidomics application to explain acute cardiotoxicity induced by doxorubicin
by: Lubna Zuhair Abdul Karim, et al.
Published: (2019-12-01)